Trial Profile

NiVOlumab for Luminal advanced/metastatic breast cancer to Taper ct-dnA In endocrine REsistance (VOLTAIRE trial)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 02 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Anastrozole; Fulvestrant; Letrozole; Palbociclib
Indications Advanced breast cancer
Focus Pharmacodynamics
Acronyms VOLTAIRE

Most Recent Events

14 Nov 2022 Results of immunogenicity analysis across various indications and by patient sex from VOLTAIRE trials (VOLTAIRE PSO, VOLTAIRE RA and VOLTAIRE CD) presented at the ACR Convergence 2022
04 Feb 2022 Status changed from recruiting to discontinued.
12 Jul 2021 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com